In November 2009, Agennix Inc merged with GPC Biotech AG of Germany to become Agennix AG, headquartered in Heidelberg, Germany and, in conseuqnce, was no longer SBIR eligible. Agennix Inc is involved in the biotechnical development of recombinant human lactoferrin or rhLF, one of the body's natural anti-infective and anti-inflammatory proteins. Agennix is focused on developing protein-based drugs for oncology and wound healing. It is reported that the firm was dissolved in 2013.
